Freyja Healthcare, LLC announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for VereSee™, the company's second-generation Mini Laparoscope with VisualEntry™ System. This regulatory milestone marks a significant advancement in minimally invasive surgery, as VereSee is designed to bring direct visualization to the earliest stage of laparoscopic entry—a critical step that traditionally occurs without visual guidance.
VereSee integrates a miniature 2mm laparoscope with Freyja's VisualEntry™ System, enabling surgeons to view anatomical structures during the entry process. This novel approach addresses a fundamental challenge in laparoscopic procedures: the initial access to the abdominal cavity, which is often performed blindly. By providing real-time visualization from the moment of entry, VereSee aims to enhance safety and precision, potentially reducing the risk of complications associated with blind trocar insertion.
“FDA clearance of VereSee is an incredibly important milestone for Freyja Healthcare,” said Mike MacKinnon, CEO of Freyja Healthcare. “We believe surgeons should have the ability to see when it matters most. VereSee brings visualization to the very beginning of the procedure while also providing the functionality of a miniature laparoscope, which may enable surgeons to avoid opening an additional laparoscope for certain procedures.”
The device is cleared as a Class II Endoscope and Accessories device under the 510(k) pathway. It pairs single-use entry components with reusable visualization technology, creating a platform that integrates into existing surgical workflows while supporting a practical economic model for healthcare providers.
Jon I. Einarsson, MD, founder of Freyja Healthcare, emphasized the broader implications: “VereSee represents more than a new method of laparoscopic entry. It is a miniature laparoscopic visualization platform that gives surgeons the opportunity to see anatomy from the moment of entry. We believe that has the potential to fundamentally change how surgeons think about access, while continuing to advance the miniaturization of laparoscopic visualization and scope functionality.”
The importance of this clearance extends beyond the product itself. It signals a shift towards enhanced visualization in minimally invasive surgery, which could improve patient outcomes by reducing the likelihood of entry-related injuries. Additionally, the ability to use the same miniature scope throughout a procedure may reduce the need for additional incisions and equipment, leading to shorter operative times and cost savings for healthcare systems.
With FDA clearance in hand, Freyja Healthcare will commence commercial introduction of VereSee, expanding access to hospitals, ambulatory surgical centers, and surgeons performing minimally invasive procedures. The company, based in Framingham, MA, focuses on developing innovative solutions for minimally invasive surgery and women's health, aiming to address unmet needs in visualization, access, and procedural efficiency.
This development is a key step forward in the evolution of laparoscopic surgery, where seeing is not just believing but also a means to enhance safety and efficacy. As Freyja Healthcare brings VereSee to market, it underscores a growing trend towards integrating advanced visualization technologies into every phase of surgical care.
